We are live on
!
Find out more
OIM
Oracle Investment Management Portfolio holdings
AUM
$168M
1-Year Est. Return
42.86%
This Fund
S&P 500
This Quarter
Est. Return
+14.3%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$136M
AUM Growth
+$32.4M
(+31%)
Cap. Flow
+$23.8M
Cap. Flow
% of AUM
17.55%
Top 10 Holdings %
Top 10 Hldgs %
79.4%
Holding
37
New
10
Increased
5
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QuidelOrtho
QDEL
|
+$4.33M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$2.25M |
| 3 |
Opko Health
OPK
|
+$2.19M |
| 4 |
GeneDx Holdings
WGS
|
+$778K |
| 5 |
Surgery Partners
SGRY
|
+$572K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DMTK
DermTech, Inc. Common Stock
DMTK
|
+$2.54M |
| 2 |
ProShares UltraPro QQQ
TQQQ
|
+$2.25M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.01M |
| 4 |
AGEN
Agenus
AGEN
|
+$1.54M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$1.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.83% |
| 2 | Energy | 0.46% |
| 3 | Technology | 0.41% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pacific Biosciences
PACB
$435M
| $26.8M | 19.75% |
2,015,495
| – | – |
|
|
2
QuidelOrtho
QDEL
$1.14B
| $20.3M | 14.99% |
245,495
+49,487
| +25% | +$4.33M |
|
3
Biohaven
BHVN
$2.03B
| $14.3M | 10.54% |
597,773
-37,703
| -6% | -$649K |
|
|
4
Opko Health
OPK
$985M
| $9.21M | 6.78% |
4,242,465
+1,399,300
| +49% | +$2.19M |
|
|
5
CALL
Surgery Partners
SGRY
$2.01B
| $7.87M | 5.8% |
+175,000
| New | +$6.68M |
|
|
6
CALL
Pacific Biosciences
PACB
$435M
| $6.85M | 5.05% |
+515,100
| New | +$6.26M |
|
|
7
CALL
QuidelOrtho
QDEL
$1.14B
| $6.81M | 5.02% |
82,200
+32,800
| +66% | +$2.87M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.51M | 4.06% |
152,600
-48,800
| -24% | -$2.01M |
|
|
9
GeneDx Holdings
WGS
$1.93B
| $5.16M | 3.8% |
865,849
+98,332
| +13% | +$778K |
|
|
AGEN
10
Agenus
AGEN
$312M
| $4.89M | 3.6% |
152,823
-48,180
| -24% | -$1.54M |
|
|
BPMC
11
CALL
DELISTED
Blueprint Medicines
BPMC
| $4.08M | 3% |
+64,500
| New | +$3.51M |
|
12
BioCryst Pharmaceuticals
BCRX
$2.28B
| $3.91M | 2.88% |
555,522
| – | – |
|
|
FORA
13
DELISTED
Forian
FORA
| $3.34M | 2.46% |
1,364,329
| – | – |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $2.62M | 1.93% |
+41,377
| New | +$2.25M |
|
15
Ardelyx
ARDX
$1.22B
| $2.37M | 1.75% |
699,700
-10,000
| -1% | -$41K |
|
|
IMMP
16
Immutep
IMMP
$56.3M
| $1.89M | 1.39% |
894,391
-456,411
| -34% | -$854K |
|
|
MRTX
17
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.81M | 1.33% |
+50,000
| New | +$2.06M |
|
|
AXDX
18
DELISTED
Accelerate Diagnostics
AXDX
| $1.22M | 0.9% |
151,065
| – | – |
|
|
19
CALL
Biohaven
BHVN
$2.03B
| $1.16M | 0.86% |
+48,600
| New | +$837K |
|
|
OMGA
20
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $1.11M | 0.81% |
197,449
-136,387
| -41% | -$1.07M |
|
|
KYNB
21
CALL
Kyntra Bio
KYNB
$27.2M
| $748K | 0.55% |
+11,080
| New | +$4.58M |
|
22
Biogen
BIIB
$30B
| $687K | 0.51% |
2,412
| – | – |
|
|
23
Surgery Partners
SGRY
$2.01B
| $675K | 0.5% |
+15,000
| New | +$572K |
|
|
VTNR
24
DELISTED
Vertex Energy, Inc
VTNR
| $628K | 0.46% |
100,400
+50,400
| +101% | +$355K |
|
25
Palantir
PLTR
$295B
| $563K | 0.41% |
+36,700
| New | +$417K |
|
Similar funds
BIO
OBWA
EECFX
PW
PWA
AIMU
HIA
ACA
Oracle Investment Management's Q2 2023 Portfolio in Review
As of Q2 2023, Oracle Investment Management held 37 positions worth $136M, up 31% from $103M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Oracle Investment Management deployed $23.8M of net new capital in Q2 2023, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was Blueprint Medicines: 41,377 shares worth $2.62M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 97% a quarter earlier, followed by Energy and Technology.
On the sell side, the largest reduction was DermTech, Inc. Common Stock, an estimated $2.54M trimmed.
- Oracle Investment Management's largest Q2 2023 buy was Blueprint Medicines: 41,377 shares worth $2.62M.
- Oracle Investment Management added most to QuidelOrtho in Q2 2023, an estimated $4.33M increase.
- Oracle Investment Management's biggest Q2 2023 reduction was DermTech, Inc. Common Stock, cutting an estimated $2.54M.
- Oracle Investment Management fully exited SpringWorks Therapeutics in Q2 2023, selling an estimated $1.12M.
- Oracle Investment Management's ten largest holdings make up 79% of its $136M portfolio in Q2 2023.
- Oracle Investment Management opened 10 new positions and closed 8 in Q2 2023.
- Oracle Investment Management's portfolio value rose 31% quarter-over-quarter to $136M.
Based on Oracle Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.